Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,341 to 1,360 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Long noncoding RNA SNHG20 promotes prostate cancer progression via upregulating DDX17. | Arch Med Sci | 2021 | 34900057 | PubTator, text mining | PubMed |
| Correction: SARS-CoV-2 suppresses IFNβ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon. | PLoS Pathog | 2021 | 34890433 | PubTator, text mining | PubMed |
| Studies on Growth Characteristics and Cross-Neutralization of Wild-Type and Delta SARS-CoV-2 From Hisar (India). | Front Cell Infect Microbiol | 2021 | 34888260 | PubTator, text mining | PubMed |
| Artificial intelligence-driven drug repurposing and structural biology for SARS-CoV-2. | Curr Res Pharmacol Drug Discov | 2021 | 34870150 | PubTator, text mining | PubMed |
| Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PLpro and Mpro/ 3CLpro: molecular docking and simulation studies of three pertinent medicinal plant natural components. | Curr Res Pharmacol Drug Discov | 2021 | 34870149 | PubTator, text mining | PubMed |
| Viral proteases: Structure, mechanism and inhibition. | Enzymes | 2021 | 34861941 | PubTator, text mining | PubMed |
| SARS-CoV-2 Nsp5 Activates NF-κB Pathway by Upregulating SUMOylation of MAVS. | Front Immunol | 2021 | 34858407 | PubTator, text mining | PubMed |
| Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence. | Sci Rep | 2021 | 34848761 | PubTator, text mining | PubMed |
| Oxidative stress transforms 3CLpro into an insoluble and more active form to promote SARS-CoV-2 replication. | Redox Biol | 2021 | 34847508 | PubTator, text mining | PubMed |
| Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview. | Vaccines (Basel) | 2021 | 34835248 | PubTator, text mining | PubMed |
| A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19. | Pharmaceutics | 2021 | 34834174 | PubTator, text mining | PubMed |
| Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. | Cells | 2021 | 34831172 | PubTator, text mining | PubMed |
| In Vitro Replication Inhibitory Activity of Xanthorrhizol against Severe Acute Respiratory Syndrome Coronavirus 2. | Biomedicines | 2021 | 34829954 | PubTator, text mining | PubMed |
| Temporal variations of country-specific mutational profile of SARS-CoV-2: effect on vaccine efficacy. | Future Virol | 2021 | 34824595 | PubTator, text mining | PubMed |
| Plug-and-play polymer microfluidic chips for hydrated, room temperature, fixed-target serial crystallography. | Lab Chip | 2021 | 34821226 | PubTator, text mining | PubMed |
| Review Devil's tools: SARS-CoV-2 antagonists against innate immunity. | Curr Res Virol Sci | 2021 | 34812428 | PubTator, text mining | PubMed |
| Genome-wide identification and prediction of SARS-CoV-2 mutations show an abundance of variants: Integrated study of bioinformatics and deep neural learning. | Inform Med Unlocked | 2021 | 34812411 | PubTator, text mining | PubMed |
| Design of modular autoproteolytic gene switches responsive to anti-coronavirus drug candidates. | Nat Commun | 2021 | 34811361 | PubTator, text mining | PubMed |
| Michaelis-like complex of SARS-CoV-2 main protease visualized by room-temperature X-ray crystallography. | IUCrJ | 2021 | 34804549 | PubTator, text mining | PubMed |
| The current state of validated small molecules inhibiting SARS-CoV-2 nonstructural proteins. | Turk J Biol | 2021 | 34803448 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=68